Literature DB >> 1333895

Radiotherapy in the treatment of hepatocellular carcinoma and its metastases.

S C Chen1, S L Lian, W L Chuang, M Y Hsieh, L Y Wang, W Y Chang, Y H Ho.   

Abstract

A study was conducted to evaluate the effect of external radiation therapy on hepatocellular carcinoma (HCC) and its metastatic lesions. A total of 33 patients with cytopathologically proven HCC were subjected to radiation therapy over a 4-year period, and treatment was discontinued in 8 cases due to jaundice, severe discomfort, or early mortality. Thus, 25 patients with 28 lesions underwent irradiation with a total dose ranging between 3000 and 5600. Of these, seven were irradiated for liver tumors, and the results showed that two lesions decreased in size, the symptoms improved in 1 case, and another patient maintained stable disease for 4 months. Among the 21 metastatic lesions treated, only 2 patients failed respond to the treatment. Nine subjects were irradiated for bone metastases, and the bone pain subsided in all but one case. The survival for bone metastasis was as long as 23 months when the primary tumor was treated effectively. Three of the four cases of irradiated skin nodules disappeared and had not recurred after 5 months, 1 year, and 4 years, respectively. Tumor shrinkage or symptoms of relief were noted for three abdominal lymph nodes, one neck lymph node, one pleural tumor, and one lung tumor. Clinical improvement associated with a stable lesion was observed in two patients with brain metastasis. Follow-up revealed regrowth of the tumor or recurrence of symptoms in most of the patients. However, none of the patients died as a direct result of a metastatic lesion. Although external radiation therapy is palliative in intent, it appears to be useful in the treatment of HCC and its metastatic lesions.

Entities:  

Mesh:

Year:  1992        PMID: 1333895     DOI: 10.1007/bf00687117

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  4 in total

1.  RADIATION HEPATITIS.

Authors:  J A INGOLD; G B REED; H S KAPLAN; M A BAGSHAW
Journal:  Am J Roentgenol Radium Ther Nucl Med       Date:  1965-01

2.  Quadruple chemotherapy versus radiotherapy in treatment of primary hepatocellular carcinoma.

Authors:  A M Cochrane; I M Murray-Lyon; D M Brinkley; R Williams
Journal:  Cancer       Date:  1977-08       Impact factor: 6.860

3.  Hepatic artery embolization in 120 patients with unresectable hepatoma.

Authors:  R Yamada; M Sato; M Kawabata; H Nakatsuka; K Nakamura; S Takashima
Journal:  Radiology       Date:  1983-08       Impact factor: 11.105

4.  Hepatic irradiation in primary and metastatic liver cancer.

Authors:  K Hatano; S Mikuriya; T Oda; M Makino; Y Hada
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

  4 in total
  5 in total

1.  The effect of external radiotherapy in treatment of portal vein invasion in hepatocellular carcinoma.

Authors:  S C Chen; S L Lian; W Y Chang
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

2.  The clinical significance of lymph node metastases in patients undergoing surgery for hepatocellular carcinoma.

Authors:  T Uenishi; K Hirohashi; T Shuto; S Kubo; H Tanaka; C Sakata; T Ikebe; H Kinoshita
Journal:  Surg Today       Date:  2000       Impact factor: 2.549

3.  Radiotherapy for multiple brain metastases from hepatocellular carcinomas.

Authors:  Nobuyuki Toshikuni; Kazuhiko Morii; Michinori Yamamoto
Journal:  World J Gastroenterol       Date:  2007-09-07       Impact factor: 5.742

Review 4.  Hepatocellular carcinoma with obstructive jaundice: diagnosis, treatment and prognosis.

Authors:  Lun-Xiu Qin; Zhao-You Tang
Journal:  World J Gastroenterol       Date:  2003-03       Impact factor: 5.742

5.  After radiotherapy, do bone metastases from gastrointestinal cancers show response rates similar to those of bone metastases from other primary cancers?

Authors:  A Hird; E Chow; D Yip; M Ross; S Hadi; C Flynn; E Sinclair; Y J Ko
Journal:  Curr Oncol       Date:  2008-10       Impact factor: 3.677

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.